Detalle Publicación

Bimonthly, treat-and-extend and as-needed ranibizumab in naïve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study
Autores: Galvez, M. I. L. (Autor de correspondencia); Barquet, L. A. ; Figueroa, M. S.; García Layana, Alfredo; Moreno, J. M. R.; In-Eye Study Group
Título de la revista: ACTA OPHTHALMOLOGICA
ISSN: 1755-375X
Volumen: 98
Número: 7
Páginas: e820 - e829
Fecha de publicación: 2020
Lugar: WOS
Purpose To assess the noninferiority of the treat-and-extend (T&E) and fixed bimonthly regimens of 0.5 mg intravitreal ranibizumab as compared with the pro re nata (PRN) in naive patients with neovascular age-related macular degeneration (nAMD). Methods Phase IV, randomized, 12-month, multicentre trial. Patients aged >= 50 years with nAMD and visual impairment [best-corrected visual acuity (BCVA) between 23 and 78 Early Treatment Diabetic Retinopathy Study (ETDRS) letters] were eligible. Patients (one eye per patient) were randomized to bimonthly, n = 103, T&E, n = 99 or PRN, n = 104. Noninferiority was established at five letters ETDRS. Results The mean (95% CI) difference in BCVA at 12 months was 7.2 (4.2-10.2), 6.4 (2.9-9.8), and 8.0 (51.1-11.0) in the bimonthly, T&E and PRN, respectively. The bimonthly or T&E regimens were not inferior to the PRN scheme. All regimens were associated with a significant reduction of central subfield thickness and volume. The mean (95% CI) number of injections in the bimonthly regimen (7.6, 7.5-7.7) was similar as compared with the PRN regimen (7.4, 6.7-8.0) (p = 0.159) but lower than in the T&E regimen (9.3, 8.9-9.7) (p < 0.001). Conclusion At 12 months, bimonthly and T&E ranibizumab were noninferior to PRN in naive nAMD.